Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 97Lung Neoplasms 35Colorectal Neoplasms 35Pancreatic Neoplasms 13Adenocarcinoma of Lung 10Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Neoplasm Metastasis 8Head and Neck Neoplasms 8Colonic Neoplasms 7Carcinoma, Renal Cell 7Ovarian Neoplasms 6Breast Neoplasms 6Rectal Neoplasms 5Melanoma 5Endometrial Neoplasms 5Stomach Neoplasms 4Adenocarcinoma, Bronchiolo-Alveolar 4Triple Negative Breast Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Recurrence 2Pleural Effusion, Malignant 2Esthesioneuroblastoma, Olfactory 2Carcinoma, Pancreatic Ductal 2

Interventions

pembrolizumab 12Nivolumab 4fludarabine 3Gemcitabine 3Drug Therapy 3Cisplatin 3spartalizumab 2budigalimab 2Injections 2Fluorodeoxyglucose F18 2Cyclophosphamide 2zenocutuzumab 1venetoclax 1ulixertinib 1tocilizumab 1tislelizumab 1seribantumab 1saracatinib 1rovalpituzumab tesirine 1pertuzumab 1pemigatinib 1niraparib 1neratinib 1milademetan 1margetuximab 1erdafitinib 1entrectinib 1cobimetinib 1cediranib 1bemarituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Cetuximab × Thoracic × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡